Binds Virus Or Component Thereof Patents (Class 424/159.1)
-
Patent number: 8586034Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.Type: GrantFiled: February 11, 2009Date of Patent: November 19, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Teresa Compton, Adam Lloyd Feire
-
Publication number: 20130302349Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Applicant: Visterra, Inc.Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
-
Publication number: 20130302350Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: April 16, 2013Publication date: November 14, 2013Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20130302351Abstract: The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof.Type: ApplicationFiled: January 31, 2012Publication date: November 14, 2013Applicant: EMORY UNIVERSITYInventors: Edmund K. Waller, Jian-Ming Li, Mohammad S. Hossain
-
Publication number: 20130302348Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Applicant: Massachusetts Institute of TechnologyInventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
-
Patent number: 8580256Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention.Type: GrantFiled: June 23, 2010Date of Patent: November 12, 2013Assignee: Yeda Reseach and Development Company LimitedInventors: Shlomo Dagan, Rachel Eren, Hemant Kumar Misra, Walter G. Gowan, Jr., Sandra O'Connor
-
Publication number: 20130295114Abstract: PVRL4 is a tumor marker that is highly expressed on the surfaces of many carcinomas. Disclosed herein are compositions and methods that provide impetus for using measles virus as an oncolytic agent against PVRL4+ carcinomas and use of PVRL4-binding agents to interfere with viral infection.Type: ApplicationFiled: January 17, 2012Publication date: November 7, 2013Inventor: Christopher D. Richardson
-
Patent number: 8574583Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided.Type: GrantFiled: November 15, 2011Date of Patent: November 5, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark Kay, Dirk Grimm
-
Patent number: 8568726Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.Type: GrantFiled: October 5, 2010Date of Patent: October 29, 2013Assignee: MedImmune LimitedInventors: Tim Beaumont, Adrianus Bakker, Etsuko Yasuda
-
Patent number: 8562996Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.Type: GrantFiled: May 30, 2008Date of Patent: October 22, 2013Assignee: MedImmune LimitedInventors: Hergen Spits, Tim Beaumont
-
Patent number: 8551484Abstract: Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: February 13, 2008Date of Patent: October 8, 2013Assignee: University of MassachusettsInventors: Donna M. Ambrosino, William D. Thomas, Jr., Gregory J. Babcock, Teresa Broering, Susan Sloan
-
Patent number: 8545848Abstract: The invention relates to neutralizing antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalized B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.Type: GrantFiled: September 14, 2012Date of Patent: October 1, 2013Assignee: Institute for Research in BiomedicineInventors: Antonia Lanzavecchia, Annalisa Macagno
-
Publication number: 20130251715Abstract: Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus H5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.Type: ApplicationFiled: May 20, 2013Publication date: September 26, 2013Applicants: NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT (NIHRD)-MINISTRY OF HEALTH, Temasek Life Sciences Laboratory LimitedInventors: Hong Liang QIAN, Fang HE, Siti Fadilah SUPARI, Hwei-Sing KWANG
-
Publication number: 20130243792Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: March 7, 2013Publication date: September 19, 2013Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H.J. Kwaks
-
Publication number: 20130243773Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: Merus B.V.Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Publication number: 20130202617Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Chengjin Michael HUANG, Jennifer Hess
-
Publication number: 20130195892Abstract: The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.Type: ApplicationFiled: September 21, 2011Publication date: August 1, 2013Inventors: Martin Beer, Ilona Reimann, Patricia Koenig
-
Publication number: 20130195893Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: ApplicationFiled: March 27, 2013Publication date: August 1, 2013Applicant: The Government of the United States of America as represented by the Secretary of the department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of He
-
Publication number: 20130189262Abstract: Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA.Type: ApplicationFiled: March 15, 2013Publication date: July 25, 2013Applicant: Five Prime Therapeutics, Inc.Inventors: Brian Wong, Jennifa Gosling
-
Publication number: 20130189275Abstract: The present invention relates to a method of interfering with dengue infection comprising interfering with dengue virus binding to a syndecan present on a cell targeted by dengue virus. The present invention further relates to treating a patient for dengue virus infection comprising administering to a patient, either having a dengue infection or a patient exposed to dengue infection, an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus.Type: ApplicationFiled: June 3, 2011Publication date: July 25, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Maria T. Arevalo, Patricia J. Simpson-Haidaris, Xia Jin, Huiyan Chen, Matthew H. Quinn
-
Publication number: 20130189279Abstract: The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.Type: ApplicationFiled: April 7, 2011Publication date: July 25, 2013Applicant: Agency for Science, Technology and ResearchInventors: Lucile Warter, Jean-Pierre Abastado, Alessandra Nardin, Cheng-I Wang
-
Publication number: 20130177573Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.Type: ApplicationFiled: July 8, 2011Publication date: July 11, 2013Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
-
Publication number: 20130171131Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: ApplicationFiled: June 22, 2012Publication date: July 4, 2013Inventors: Christopher C. Broder, Katharine N. Bossart
-
Publication number: 20130171132Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: ApplicationFiled: June 22, 2012Publication date: July 4, 2013Inventors: Christopher C. Broder, Katharine N. Bossart
-
Publication number: 20130171169Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20130164306Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.Type: ApplicationFiled: November 15, 2012Publication date: June 27, 2013Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventor: SANFORD-BURNHAM MEDICAL RESEARCH IN
-
Publication number: 20130164307Abstract: The invention provides methods, compositions, and kits featuring a camelid-derived antibody for use in preventing or inhibiting a viral infection.Type: ApplicationFiled: June 17, 2011Publication date: June 27, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Richard B. Markham
-
Publication number: 20130164289Abstract: Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (CMV) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the UL130 and UL131 components of the gH/gL/UL128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of UL130 and amino acid residues 90-106 of UL131. The combination peptides, polypeptides and proteins, and the nucleic acids encoding them, may be used in vaccines, and as diagnostic and research tools.Type: ApplicationFiled: September 9, 2011Publication date: June 27, 2013Applicant: Virginia Commonwealth UniversityInventors: Michael McVoy, Stuart Adler, Xiaohong Cui
-
Patent number: 8470327Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.Type: GrantFiled: May 6, 2010Date of Patent: June 25, 2013Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Robert Heinz Edward Friesen, Theodorus Hendrikus Jacobus Kwaks, Mandy Antonia Catharina Jongeneelen
-
Publication number: 20130156791Abstract: The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing human immunodeficiency virus type 1 (HIV-1) infection. More particularly, the present invention relates to a blocking agent of a component of the purinergic signalling pathway selected from the group consisting of pannexin 1, ATP or P2Y2 receptor for use in the treatment or prevention of HIV-1 infection.Type: ApplicationFiled: August 8, 2011Publication date: June 20, 2013Inventors: Jean-luc Perfettini, Guido Kroemer, Marie-Lise Gougeon, Mauro Placentini
-
Publication number: 20130129747Abstract: The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies. Further provided are novel antibodies against influenza.Type: ApplicationFiled: July 22, 2011Publication date: May 23, 2013Inventor: John W. Schrader
-
Patent number: 8444986Abstract: Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus K5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.Type: GrantFiled: August 26, 2008Date of Patent: May 21, 2013Assignee: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Siti Fadilah Supari, Hwei-Sing Kwang
-
Patent number: 8435524Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: September 10, 2012Date of Patent: May 7, 2013Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Publication number: 20130108649Abstract: Methods and uses for the treatment of herpesvirus infection based on the inhibition of the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a) are described.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Institut National De La Recherche Scientifique
-
Publication number: 20130101604Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Patent number: 8407912Abstract: The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.Type: GrantFiled: March 8, 2012Date of Patent: April 2, 2013Assignee: Velico Medical, Inc.Inventors: Dennis Brian Hubbard, Jr., Michael Haley
-
Publication number: 20130078261Abstract: The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.Type: ApplicationFiled: November 19, 2012Publication date: March 28, 2013Applicant: Baxter Healthcare S.A.Inventor: Baxter Healthcare S.A.
-
Publication number: 20130058952Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: ApplicationFiled: October 1, 2010Publication date: March 7, 2013Inventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Edelgard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer
-
Patent number: 8387269Abstract: The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.Type: GrantFiled: March 8, 2012Date of Patent: March 5, 2013Assignee: Velico Medical, Inc.Inventors: Dennis Brian Hubbard, Jr., Michael Haley
-
Publication number: 20130039926Abstract: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.Type: ApplicationFiled: July 19, 2012Publication date: February 14, 2013Applicants: Center for Disease Control and Prevention, University of MassachusettsInventors: William D. Thomas, JR., Donna M. Ambrosino, Robert Mandell, Susan Sloan, Gregory J. Babcock, Charles Rupprecht
-
ANTIGENIC MIMICS OF DISCONTINUOUS EPITOPES OF PATHOGEN RECOGNIZED BY BROADLY NEUTRALIZING ANTIBODIES
Publication number: 20130039927Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.Type: ApplicationFiled: February 14, 2011Publication date: February 14, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Stephen Dewhurst, Mark A. Sullivan -
Publication number: 20130034500Abstract: The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).Type: ApplicationFiled: June 29, 2012Publication date: February 7, 2013Inventors: Paul B. Savage, Donald Y.M. Leung
-
Publication number: 20130028913Abstract: Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops.Type: ApplicationFiled: December 1, 2010Publication date: January 31, 2013Inventors: Barbara Leuchs, Kathrin Kürschner, Andrea Kuck, Marcus Müller, Silvia Münstermann, Jean Rommelaere
-
Patent number: 8361473Abstract: Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies.Type: GrantFiled: March 27, 2008Date of Patent: January 29, 2013Assignee: Technion Research & Development Foundation Ltd.Inventors: Oryan Makler, Yoram Reiter
-
Patent number: 8359766Abstract: The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.Type: GrantFiled: March 8, 2012Date of Patent: January 29, 2013Assignee: Velico Medical, Inc.Inventors: Dennis Brian Hubbard, Jr., Michael Haley
-
Publication number: 20130022618Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: September 10, 2012Publication date: January 24, 2013Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20130004497Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
-
Publication number: 20130004496Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
-
Publication number: 20120328626Abstract: Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the Leishmania major STT3D protein, in the presence of expression of the host cell genes encoding the endogenous OTase complex.Type: ApplicationFiled: February 23, 2011Publication date: December 27, 2012Inventors: Natarajan Sethuraman, Byung-Kwon Choi, Bianka Prinz, Michael Meehl, Terrance Stadheim
-
Patent number: 8337854Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (Fc?R) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.Type: GrantFiled: April 3, 2008Date of Patent: December 25, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai